Grade 3 and 4 Toxicity Profiles During Therapy of Childhood Acute Lymphoblastic Leukemia

Joanna Zawitkowska(Poznan University of Medical Sciences), Jerzy Kowalczyk(Poznan University of Medical Sciences), Katarzyna Drabko(Medical University of Lublin), Magdalena Ćwiklińska(Uniwersytecki Szpital Dziecięcy), Michał Romiszewski(Children's Memorial Health Institute), Monika Lejman(Medical University of Lublin), Grażyna Karolczyk, Joanna Trelińska(Medical University of Lodz), Marcin Płonowski(Medical University of Białystok), Maciej Niedźwiecki(Gdańsk Medical University), Katarzyna Derwich(Poznan University of Medical Sciences), Aleksandra Kiermasz(Lublin Oncology Center), Agnieszka Zaucha‐Prażmo(Medical University of Lublin), Joanna Owoc‐Lempach(Wroclaw Medical University), Andrzej Kołtan(Collegium Medicum in Bydgoszcz), Joanna Bulsa(Medical University of Silesia), Tomasz Ociepa(Pomeranian Medical University), Agnieszka Mizia‐Malarz(Medical University of Silesia)
In Vivo
January 1, 2019
10.21873/invivo.11608
Cited by 27

Related Papers

Results and factors influencing outcome after fully haploidentical hematopoietic stem cell transplantation in children with very high-risk acute lymphoblastic leukemia: impact of center size: an analysis on behalf of the Acute Leukemia and Pediatric Disease Working Parties of the European Blood and Marrow Transplant group
|Blood|2009|181
The New Therapeutic Strategies in Pediatric T-Cell Acute Lymphoblastic Leukemia
|International Journal of Molecular Sciences|2021|81
Genetic Biomarkers and Their Clinical Implications in B-Cell Acute Lymphoblastic Leukemia in Children
|International Journal of Molecular Sciences|2022|74
Recent Advances in Treatment Options for Childhood Acute Lymphoblastic Leukemia
|Cancers|2022|61
Neurotoxicity Associated with Treatment of Acute Lymphoblastic Leukemia Chemotherapy and Immunotherapy
|International Journal of Molecular Sciences|2022|58